uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.30−0.48 (-2.31%)
Close on Nov 18, 2026Market cap $1.41BP/E –Yield –
uniQure price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
uniQure's price to sales ratio was 91.3× on Nov 11, 2026, against 108.6× a year earlier. Over the last 5 years it ranged from 1.3× to 259.0×, with a median of 15.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 91.3× | −3.2 |
| 2025 | Dec 31, 2025 | 94.4× | +64.3 |
| 2024 | Dec 31, 2024 | 30.1× | +27.2 |
| 2023 | Dec 29, 2023 | 2.9× | −14.4 |
| 2022 | Dec 30, 2022 | 17.3× | +15.4 |
| 2021 | Dec 31, 2021 | 1.9× | −263.6 |
| 2020 | Dec 31, 2020 | 265.5× | −233.4 |
| 2019 | Dec 31, 2019 | 498.9× | +411.3 |
| 2018 | Dec 31, 2018 | 87.6× | +62.1 |
| 2017 | Dec 29, 2017 | 25.6× | +12.7 |
| 2016 | Dec 30, 2016 | 12.9× | −33.2 |
| 2015 | Dec 31, 2015 | 46.1× | – |
See a number that looks wrong?